E-submission
Search
- Page Path
- HOME > Search
Original Article
- Clinicopathologic Implication of Ezrin Expression in Non-small Cell Lung Cancer
- Ho Won Lee, Eui Han Kim, Mee-Hye Oh
- Korean J Pathol. 2012;46(5):470-477. Published online October 25, 2012
- DOI: https://doi.org/10.4132/KoreanJPathol.2012.46.5.470
- 8,156 View
- 25 Download
- 14 Crossref
-
Abstract
PDF Background Ezrin, a member of the ezrin-radixin-moesin family, is implicated in tumor progression, metastatic dissemination, and adverse outcomes, in several cancer types. In this study, we explored the clinicopathological significance of ezrin expression in non-small cell lung carcinomas (NSCLCs).
Methods Immunohistochemical analysis of tissue microarray with 112 surgically resected NSCLC specimens, was performed to examine the ezrin expression. We also correlated ezrin expression with other clinicopathological features and prognosis.
Results The ezrin-positive group revealed significantly higher correlation with pleural invasion (p=0.016) and pathologic stage (p=0.050). Univariate survival analysis showed that ezrin-positive group had a significantly shorter cancer-specific survival than ezrin-negative group (p=0.016). Meanwhile, female (p=0.030), no pleural invasion (p=0.023), no lymphatic invasion (p=0.026), and early pathologic stage (p=0.008) significantly correlated with longer survival. Multivariate survival analysis showed that variables such as ezrin positivity (p=0.032), female (p=0.035), and early pathologic stage (p=0.001) were independent prognostic factors for NSCLC.
Conclusions Ezrin might be a molecular marker to predict poor prognosis of NSCLC.
-
Citations
Citations to this article as recorded by
- Perspectives for Targeting Ezrin in Cancer Development and Progression
Jean Carlos Lipreri da Silva, Hugo Passos Vicari, João Agostinho Machado-Neto
Future Pharmacology.2023; 3(1): 61. CrossRef - CIGB-300 Anticancer Peptide Differentially Interacts with CK2 Subunits and Regulates Specific Signaling Mediators in a Highly Sensitive Large Cell Lung Carcinoma Cell Model
George V. Pérez, Mauro Rosales, Ailyn C. Ramón, Arielis Rodríguez-Ulloa, Vladimir Besada, Luis J. González, Daylen Aguilar, Dania Vázquez-Blomquist, Viviana Falcón, Evelin Caballero, Paulo C. Carvalho, Rodrigo Soares Caldeira, Ke Yang, Yasser Perera, Silv
Biomedicines.2022; 11(1): 43. CrossRef - Increased Tumor Growth Rate and Mesenchymal Properties of NSCLC-Patient-Derived Xenograft Models during Serial Transplantation
José Miguel Pardo-Sánchez, Nuria Mancheño, José Cerón, Carlos Jordá, Emilio Ansotegui, Óscar Juan, Sarai Palanca, Antonio Cremades, Carolina Gandía, Rosa Farràs
Cancers.2021; 13(12): 2980. CrossRef - Loss of ARID1A expression is associated with poor prognosis in non-small cell lung cancer
Si-Hyong Jang, Ji-Hye Lee, Hyun Ju Lee, Hyundeuk Cho, Hyein Ahn, In Hag Song, Mee-Hye Oh
Pathology - Research and Practice.2020; 216(11): 153156. CrossRef - Ezrin Mediates Invasion and Metastasis in Tumorigenesis: A Review
Yanan Song, Xiaokun Ma, Miao Zhang, Menghan Wang, Guoyu Wang, Ying Ye, Wei Xia
Frontiers in Cell and Developmental Biology.2020;[Epub] CrossRef - Correlation of Ezrin Expression Pattern and Clinical Outcomes in Ewing Sarcoma
Thomas Cash, Hong Yin, Courtney McCracken, Zhi Geng, Steven G. DuBois, Bahig M. Shehata, Thomas A. Olson, Howard M. Katzenstein, Cynthia Wetmore
Sarcoma.2017; 2017: 1. CrossRef - Prognostic and Clinicopathological Significance of Transducer-Like Enhancer of Split 1 Expression in Gastric Cancer
Ji-Hye Lee, Myoung-Won Son, Kyung-Ju Kim, Mee-Hye Oh, Hyundeuk Cho, Hyun Ju Lee, Si-Hyong Jang, Moon Soo Lee
Journal of Gastric Cancer.2016; 16(1): 21. CrossRef - Significance of DEK overexpression for the prognostic evaluation of non-small cell lung carcinoma
XIN LIU, DONGDONG QI, JUJIE QI, ZESHU MAO, XIANGDAN LI, JINHUI ZHANG, JINZI LI, WENBIN GAO
Oncology Reports.2016; 35(1): 155. CrossRef - Silencing of high‐mobility group box 2 (HMGB2) modulates cisplatin and 5‐fluorouracil sensitivity in head and neck squamous cell carcinoma
Nazia Syed, Sandip Chavan, Nandini A. Sahasrabuddhe, Santosh Renuse, Gajanan Sathe, Vishalakshi Nanjappa, Aneesha Radhakrishnan, Remya Raja, Sneha M. Pinto, Anand Srinivasan, T. S. Keshava Prasad, Kotteazeth Srikumar, Harsha Gowda, Vani Santosh, David Sid
PROTEOMICS.2015; 15(2-3): 383. CrossRef - Prognostic Value of Ezrin in Various Cancers: A Systematic Review and Updated Meta-analysis
Jianwei Li, Kuanhai Wei, Hailang Yu, Dan Jin, Gang Wang, Bin Yu
Scientific Reports.2015;[Epub] CrossRef - Radixin Enhances Colon Cancer Cell Invasion by Increasing MMP-7 Production via Rac1-ERK Pathway
Qi-Hong Jiang, Ai-Xiang Wang, Yan Chen
The Scientific World Journal.2014; 2014: 1. CrossRef - Clinical significance of microRNA-183/Ezrin axis in judging the prognosis of patients with osteosarcoma
Yisila Mu, Haoshaqiang Zhang, Lixin Che, Kun Li
Medical Oncology.2014;[Epub] CrossRef - Prognostic implications of ezrin and phosphorylated ezrin expression in non-small cell lung cancer
Tiefeng Jin, Jingchun Jin, Xiangyu Li, Songnan Zhang, Yun Ho Choi, Yingshi Piao, Xionghu Shen, Zhenhua Lin
BMC Cancer.2014;[Epub] CrossRef - Prognostic Value of Ezrin in Solid Tumors: A Meta-Analysis of the Literature
Kun Han, WeiXiang Qi, ZhiHua Gan, Zan Shen, Yang Yao, DaLiu Min, Yves St-Pierre
PLoS ONE.2013; 8(7): e68527. CrossRef
- Perspectives for Targeting Ezrin in Cancer Development and Progression
Clinical Trial
- Prognostic Significance of Ezrin Expression in Liposarcoma.
- Jae Seok Lee, Min Sun Jin, Jung Eun Lee, Min Suk Kim, Dae Geun Jeon, Jae Soo Koh
- Korean J Pathol. 2008;42(5):270-276.
- 1,628 View
- 13 Download
-
Abstract
PDF
- BACKGROUND
Ezrin has been reported to be involved in the metastasis of solid tumors in both an animal model and clinical trials. However, questions remains as to whether an ezrin expression is an independent predictor of the event-free survival of liposarcoma patients. METHODS: We analyzed 85 liposarcoma patients without metastasis at the time of presentation. We performed immunohistochemistry with anti-ezrin antibody, and we analyzed the association of an ezrin expression with the clinicopathological variables and event-free survival. RESULTS: Twenty-nine patients (34.1%) showed an ezrin expression. Among the 30 low-grade liposarcoma patients, only one patient showed ezrin positivity. The patients who had an ezrin expression were found to be at a significantly increased risk for metastasis compared with the patients who had no ezrin expression (risk ratio: 3.4, 95% confidence interval: 1.3-9.1). The 10-year metastasis-free survival rate was 26.9% for the patients with an ezrin expression and 86.7% for the patients without an ezrin expression. The ezrin expression rate increased with an advanced tumor grade and stage. CONCLUSION: An ezrin expression is an independent predictor of distant metastasis for liposarcoma. Thus, ezrin has the potential to provide additional prognostic information and to be a novel target for the development of new adjuvant therapies for treating the patients who suffer from liposarcoma.
First
Prev
